130 related articles for article (PubMed ID: 3210248)
1. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone.
Herbette LG; Trumbore M; Chester DW; Katz AM
J Mol Cell Cardiol; 1988 May; 20(5):373-8. PubMed ID: 3210248
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism.
Young HS; Skita V; Mason RP; Herbette LG
Biophys J; 1992 May; 61(5):1244-55. PubMed ID: 1318093
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of the interaction of propranolol and timolol with model and biological membrane systems.
Herbette L; Katz AM; Sturtevant JM
Mol Pharmacol; 1983 Sep; 24(2):259-69. PubMed ID: 6888369
[TBL] [Abstract][Full Text] [Related]
4. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
Mason RP; Campbell SF; Wang SD; Herbette LG
Mol Pharmacol; 1989 Oct; 36(4):634-40. PubMed ID: 2554114
[TBL] [Abstract][Full Text] [Related]
5. Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors.
Herbette LG; Vant Erve YM; Rhodes DG
J Mol Cell Cardiol; 1989 Feb; 21(2):187-201. PubMed ID: 2545886
[TBL] [Abstract][Full Text] [Related]
6. Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes.
Mason RP; Gonye GE; Chester DW; Herbette LG
Biophys J; 1989 Apr; 55(4):769-78. PubMed ID: 2470429
[TBL] [Abstract][Full Text] [Related]
7. Structure and location of amiodarone in a membrane bilayer as determined by molecular mechanics and quantitative x-ray diffraction.
Trumbore M; Chester DW; Moring J; Rhodes D; Herbette LG
Biophys J; 1988 Sep; 54(3):535-43. PubMed ID: 3207838
[TBL] [Abstract][Full Text] [Related]
8. The separate profile structures of the functional calcium pump protein and the phospholipid bilayer within isolated sarcoplasmic reticulum membranes determined by X-ray and neutron diffraction.
Herbette L; DeFoor P; Fleischer S; Pascolini D; Scarpa A; Blasie JK
Biochim Biophys Acta; 1985 Jul; 817(1):103-22. PubMed ID: 3159429
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of amiodarone and propranolol on lipid dynamics and enzymatic activities in cardiac sarcolemmal membranes.
Chatelain P; Laruel R; Vic P; Brotelle R
Biochem Pharmacol; 1989 Apr; 38(8):1231-9. PubMed ID: 2539821
[TBL] [Abstract][Full Text] [Related]
10. Interaction of amphiphilic molecules with biological membranes. A model for nonspecific and specific drug effects with membranes.
Herbette L; Napolitano CA; Messineo FC; Katz AM
Adv Myocardiol; 1985; 5():333-46. PubMed ID: 3969518
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer.
Mason RP; Moisey DM; Shajenko L
Mol Pharmacol; 1992 Feb; 41(2):315-21. PubMed ID: 1531693
[TBL] [Abstract][Full Text] [Related]
12. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location.
Bäuerle HD; Seelig J
Biochemistry; 1991 Jul; 30(29):7203-11. PubMed ID: 1830218
[TBL] [Abstract][Full Text] [Related]
13. Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes.
Herbette LG; Mason PE; Sweeney KR; Trumbore MW; Mason RP
Neuropharmacology; 1994 Feb; 33(2):241-9. PubMed ID: 8035910
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study.
Breuel HP; Heine PR; Mück W; Niklaus H; Schmage N; Kuhlmann J
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):103-8. PubMed ID: 7757308
[TBL] [Abstract][Full Text] [Related]
15. A neutron diffraction study of the headgroup conformation of phosphatidylglycerol from Escherichia coli membranes.
Mischel M; Seelig J; Braganza LF; Büldt G
Chem Phys Lipids; 1987 May; 43(4):237-46. PubMed ID: 3301024
[TBL] [Abstract][Full Text] [Related]
16. Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers.
Chester DW; Herbette LG; Mason RP; Joslyn AF; Triggle DJ; Koppel DE
Biophys J; 1987 Dec; 52(6):1021-30. PubMed ID: 2447967
[TBL] [Abstract][Full Text] [Related]
17. Molecular interaction between lacidipine and biological membranes.
Herbette LG; Gaviraghi G; Tulenko T; Mason RP
J Hypertens Suppl; 1993 Mar; 11(1):S13-9. PubMed ID: 8387105
[TBL] [Abstract][Full Text] [Related]
18. Calorimetric, x-ray diffraction, and spectroscopic studies of the thermotropic phase behavior and organization of tetramyristoyl cardiolipin membranes.
Lewis RN; Zweytick D; Pabst G; Lohner K; McElhaney RN
Biophys J; 2007 May; 92(9):3166-77. PubMed ID: 17293402
[TBL] [Abstract][Full Text] [Related]
19. Interactions of beta-blockers with model lipid membranes: molecular view of the interaction of acebutolol, oxprenolol, and propranolol with phosphatidylcholine vesicles by time-dependent fluorescence shift and molecular dynamics simulations.
Först G; Cwiklik L; Jurkiewicz P; Schubert R; Hof M
Eur J Pharm Biopharm; 2014 Aug; 87(3):559-69. PubMed ID: 24681296
[TBL] [Abstract][Full Text] [Related]
20. Octyl-beta-D-glucopyranoside partitioning into lipid bilayers: thermodynamics of binding and structural changes of the bilayer.
Wenk MR; Alt T; Seelig A; Seelig J
Biophys J; 1997 Apr; 72(4):1719-31. PubMed ID: 9083676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
